SCHEMBL17697709

SCHEMBL17697709

O=[N+]([O-])c1ccc2ncc(S(=O)(=O)Cl)n2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 3/20 0.43
CYP2C9 P11712 2/20 0.43
MAPT P10636 2/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
PARL Q9H300 1/20 0.38
PIK3CB P42338 3/20 0.37
PIK3C2B O00750 2/20 0.37
PIK3CG P48736 2/20 0.37
PIK3CD O00329 1/20 0.36
DYRK3 O43781 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK2 P24941 1/20 0.36
FLT3 P36888 1/20 0.36
PIK3CA P42336 1/20 0.36
CSNK1E P49674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17697692 0.76 POLB (0.46) MEN1KMT2AFLT3CDK7NPC1
SCHEMBL4465794 0.75 CYP1A2 (0.54) CYP1A2MEN1KMT2AALDH1A1CYP2C9
SCHEMBL17697688 0.75 MAP3K14 (0.41) PIK3CBPIK3C2BPIK3CGPIK3CDDYRK3
SCHEMBL30218146 0.75 CYP1A2 (0.49) CYP1A2MEN1KMT2AALDH1A1CYP2C9
SCHEMBL31141900 0.75 CYP1A2 (0.49) CYP1A2MEN1KMT2AALDH1A1CYP2C9
SCHEMBL17759257 0.73 CYP1A2 (0.46) CYP1A2MEN1KMT2AALDH1A1CYP2C9
SCHEMBL17673 0.67 CA2 (0.61) ALDH1A1LMNAPARL
SCHEMBL1134371 0.66 AGTR1 (0.61) CYP1A2MEN1KMT2AALDH1A1CYP2C9
Hydrochloric Acid SCHEMBL7567770 0.66 CA2 (0.59) ALDH1A1LMNAPARL
SCHEMBL6256244 0.66 PIK3C2B (0.49) CYP1A2MEN1KMT2AALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3012259-B1 FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-06-03 EP disclosed
US-9988381-B2 Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-06-05 US disclosed
US-20160137640-A1 FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF SHANGHAI HAIHE PHARMACEUTICAL CO. LTD. (CN) 2016-05-19 US disclosed
EP-3012259-A1 FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2016-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137640-A1 FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF ABL1, JAK2, LCK CYP1A2 782/4885MEN1 1177/4885KMT2A 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.